A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE

Active:	Yes
Cancer Type:	Liver Cancer / Hepatoblastoma	NCT ID:	NCT06040099
Trial Phases:	Phase II	Protocol IDs:	D933GC00002 (primary) NCI-2023-10167
Eligibility:	18 - 130 Years, Male and Female	Study Type:	Treatment
Study Sponsor:	AstraZeneca Pharmaceuticals LP
NCI Full Details:	http://clinicaltrials.gov/show/NCT06040099

Summary

The purpose of this study is to measure the efficacy and safety of durvalumab intravenous
(IV) solution plus bevacizumab IV solution after transarterial radioembolization (Yttrium
90 glass microspheres TARE) in participants with unresectable hepatocellular carcinoma
(HCC) amenable to embolization.

Objectives

A Phase II single-arm study conducted in participants with unresectable Hepatocellular
carcinoma (HCC) eligible for embolization and not eligible for or who have declined
treatment with resection and/or ablation or liver transplant.

Participants with previous Transarterial Chemoembolization (TACE) or TARE associated with
the curative setting are permitted with a 6-month washout.

Approximately 125 participants with unresectable but amenable to locoregional therapy HCC
eligible for embolization will be enrolled in the study at approximately 20 sites in the
US to treat approximately 100 participants.

Treatment Sites in Georgia

Northside Hospital Cancer Institute
1000 Johnson Ferry Road NE
Atlanta, GA 30342
404-303-3355
www.northside.com

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
404-778-5180
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.